• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.雷夫康唑（BMS-207147）对541株新型隐球菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2000 Oct;44(10):2883-6. doi: 10.1128/AAC.44.10.2883-2886.2000.
2
In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.伏立康唑、氟康唑和伊曲康唑对来自美国和非洲的566株新生隐球菌临床分离株的体外活性。
Antimicrob Agents Chemother. 1999 Jan;43(1):169-71. doi: 10.1128/AAC.43.1.169.
3
In vitro activities of posaconazole, ravuconazole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species.泊沙康唑、雷夫康唑、特比萘芬、伊曲康唑和氟康唑对皮肤癣菌、酵母菌及非皮肤癣菌属的体外活性。
Med Mycol. 2005 Mar;43(2):179-85. doi: 10.1080/13693780410001731583.
4
In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.泊沙康唑（Sch 56592）与伊曲康唑和氟康唑相比，对3685株念珠菌属和新型隐球菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2001 Oct;45(10):2862-4. doi: 10.1128/AAC.45.10.2862-2864.2001.
5
In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.在体外对从塞尔维亚患者脑脊液和血液中分离的新型隐球菌的两性霉素 B、5-氟胞嘧啶、氟康唑和伊曲康唑的抗真菌活性。
J Mycol Med. 2012 Sep;22(3):243-8. doi: 10.1016/j.mycmed.2012.06.002. Epub 2012 Aug 10.
6
In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates.雷夫康唑与其他四种抗真菌药物对氟康唑耐药或敏感临床酵母分离株的体外活性。
Antimicrob Agents Chemother. 2004 Aug;48(8):3107-11. doi: 10.1128/AAC.48.8.3107-3111.2004.
7
Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformans in Goiânia city, Goiás, Brazil.巴西戈亚斯州戈亚尼亚市新型隐球菌临床和环境分离株的抗真菌药敏性
Rev Inst Med Trop Sao Paulo. 2005 Sep-Oct;47(5):253-6. doi: 10.1590/s0036-46652005000500003. Epub 2005 Nov 16.
8
In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.伏立康唑和伊曲康唑对氟康唑敏感及耐药新生隐球菌分离株的体外比较疗效
Antimicrob Agents Chemother. 1998 Feb;42(2):471-2. doi: 10.1128/AAC.42.2.471.
9
Antifungal susceptibility of Cryptococcus neoformans isolates in HIV-infected patients to fluconazole, itraconazole and voriconazole in Spain: 1994-1996 and 1997-2005.西班牙1994 - 1996年及1997 - 2005年HIV感染患者中新型隐球菌分离株对氟康唑、伊曲康唑和伏立康唑的抗真菌药敏情况
Chemotherapy. 2007;53(4):300-5. doi: 10.1159/000102585. Epub 2007 May 10.
10
Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.泊沙康唑、雷夫康唑和伏立康唑与伊曲康唑及两性霉素B相比，对239株曲霉属及其他丝状真菌临床分离株的抗真菌活性：2000年SENTRY抗菌监测项目报告
Antimicrob Agents Chemother. 2002 Apr;46(4):1032-7. doi: 10.1128/AAC.46.4.1032-1037.2002.

引用本文的文献

1
Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.筛选大流行应对框，确定苯并咪唑氨基甲酸酯、奥洛福米和拉夫康唑为治疗外耳真菌病的有希望的药物候选物。
PLoS Negl Trop Dis. 2022 Feb 4;16(2):e0010159. doi: 10.1371/journal.pntd.0010159. eCollection 2022 Feb.
2
The Antifungal Activity of HMA, an Amiloride Analog and Inhibitor of Na/H Exchangers.氨氯吡脒类似物HMA（钠/氢交换体抑制剂）的抗真菌活性
Front Microbiol. 2021 May 5;12:673035. doi: 10.3389/fmicb.2021.673035. eCollection 2021.
3
Activities of Ravuconazole and Isavuconazole against Dematiaceous Fungi.拉夫康唑和伊曲康唑对暗色真菌的活性。
Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.00643-20.
4
Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.新型口服三唑类抗真菌药物伏立康唑赖氨酸乙酯治疗甲真菌病的疗效和安全性：一项多中心、双盲、随机 III 期研究。
J Dermatol. 2018 Oct;45(10):1151-1159. doi: 10.1111/1346-8138.14607. Epub 2018 Aug 29.
5
Madurella mycetomatis is highly susceptible to ravuconazole.米卡多毛孢菌对拉夫康唑高度敏感。
PLoS Negl Trop Dis. 2014 Jun 19;8(6):e2942. doi: 10.1371/journal.pntd.0002942. eCollection 2014 Jun.
6
In vitro studies of the activity of dithiocarbamate organoruthenium complexes against clinically relevant fungal pathogens.二硫代氨基甲酸盐有机钌配合物对临床相关真菌病原体活性的体外研究。
Molecules. 2014 Apr 24;19(4):5402-20. doi: 10.3390/molecules19045402.
7
In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates.对全球范围内 350 株临床、兽医和环境分离的隐球菌的体外抗真菌药敏试验和扩增片段长度多态性基因分型研究。
Antimicrob Agents Chemother. 2010 Dec;54(12):5139-45. doi: 10.1128/AAC.00746-10. Epub 2010 Sep 20.
8
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore.含腈类药物：腈药效基团的有效作用
J Med Chem. 2010 Nov 25;53(22):7902-17. doi: 10.1021/jm100762r. Epub 2010 Aug 30.
9
Heteroresistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence.新型隐球菌对氟康唑的异质性耐药是内在的，且与毒力相关。
Antimicrob Agents Chemother. 2009 Jul;53(7):2804-15. doi: 10.1128/AAC.00295-09. Epub 2009 May 4.
10
In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.雷夫康唑对923株非皮肤癣菌丝状真菌临床分离株的体外活性。
Antimicrob Agents Chemother. 2005 Dec;49(12):5136-8. doi: 10.1128/AAC.49.12.5136-5138.2005.

本文引用的文献

1
In vitro activities of BMS-207147 against over 600 contemporary clinical bloodstream isolates of Candida species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America.BMS-207147对来自北美和拉丁美洲哨兵抗菌监测计划的600多株当代临床念珠菌血流分离株的体外活性。
Antimicrob Agents Chemother. 1999 Sep;43(9):2236-9. doi: 10.1128/AAC.43.9.2236.
2
In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa.伏立康唑、氟康唑和伊曲康唑对来自美国和非洲的566株新生隐球菌临床分离株的体外活性。
Antimicrob Agents Chemother. 1999 Jan;43(1):169-71. doi: 10.1128/AAC.43.1.169.
3
New azole antifungals. 3. Synthesis and antifungal activity of 3-substituted-4(3H)-quinazolinones.新型唑类抗真菌剂。3. 3-取代-4(3H)-喹唑啉酮的合成及抗真菌活性
J Med Chem. 1998 May 21;41(11):1869-82. doi: 10.1021/jm9707277.
4
Synthesis and antifungal activity of novel thiazole-containing triazole antifungals. II. Optically active ER-30346 and its derivatives.新型含噻唑三唑类抗真菌剂的合成与抗真菌活性。II. 光学活性ER-30346及其衍生物。
Chem Pharm Bull (Tokyo). 1998 Apr;46(4):623-30. doi: 10.1248/cpb.46.623.
5
In vitro comparative efficacy of voriconazole and itraconazole against fluconazole-susceptible and -resistant Cryptococcus neoformans isolates.伏立康唑和伊曲康唑对氟康唑敏感及耐药新生隐球菌分离株的体外比较疗效
Antimicrob Agents Chemother. 1998 Feb;42(2):471-2. doi: 10.1128/AAC.42.2.471.
6
In vitro activity of a new oral triazole, BMS-207147 (ER-30346).新型口服三唑类药物BMS-207147（ER-30346）的体外活性
Antimicrob Agents Chemother. 1998 Feb;42(2):313-8. doi: 10.1128/AAC.42.2.313.
7
The hidden danger of primary fluconazole prophylaxis for patients with AIDS.艾滋病患者氟康唑初级预防的隐患。
Clin Infect Dis. 1998 Jan;26(1):186-7. doi: 10.1086/517056.
8
Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.抗真菌药敏试验解释性断点的制定：氟康唑、伊曲康唑和念珠菌感染的体外-体内相关性数据的概念框架与分析。美国国家临床实验室标准委员会抗真菌药敏试验小组委员会
Clin Infect Dis. 1997 Feb;24(2):235-47. doi: 10.1093/clinids/24.2.235.
9
Efficacy of ER-30346, a novel oral triazole antifungal agent, in experimental models of aspergillosis, candidiasis, and cryptococcosis.新型口服三唑类抗真菌药ER-30346在曲霉病、念珠菌病和隐球菌病实验模型中的疗效。
Antimicrob Agents Chemother. 1996 Oct;40(10):2243-7. doi: 10.1128/AAC.40.10.2243.
10
In vitro and in vivo antifungal activities of ER-30346, a novel oral triazole with a broad antifungal spectrum.新型口服三唑类抗真菌药ER-30346的体外和体内抗真菌活性，其具有广谱抗真菌谱。
Antimicrob Agents Chemother. 1996 Oct;40(10):2237-42. doi: 10.1128/AAC.40.10.2237.

雷夫康唑（BMS-207147）对541株新型隐球菌临床分离株的体外活性。

In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.

作者信息

Yamazumi T, Pfaller M A, Messer S A, Houston A, Hollis R J, Jones R N

机构信息

Medical Microbiology Division, Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242, USA.

出版信息

Antimicrob Agents Chemother. 2000 Oct;44(10):2883-6. doi: 10.1128/AAC.44.10.2883-2886.2000.

DOI:10.1128/AAC.44.10.2883-2886.2000
PMID:10991880
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC90171/
Abstract

The in vitro activities of the new triazole, ravuconazole (BMS-207147), were compared to those of fluconazole and itraconazole against 541 clinical isolates of Cryptococcus neoformans. Isolates were obtained from cerebrospinal fluid (396), blood (116), and miscellaneous clinical specimens (29). Overall, ravuconazole (MIC at which 90% of the isolates are inhibited [MIC(90)], 0.25 microg/ml) was more active than either itraconazole (MIC(90), 0.5 microg/ml) or fluconazole (MIC(90), 8 microg/ml). Among the isolates inhibited by > or =16 microg of fluconazole/ml, 90.2% were inhibited by < or =1 microg of ravuconazole/ml. On the basis of our findings and the favorable pharmacokinetic properties of ravuconazole, we suggest that ravuconazole may be useful for the treatment of infectious diseases due to C. neoformans and that further clinical studies to confirm these promising in vitro results are warranted.

摘要

将新型三唑类药物ravuconazole（BMS - 207147）的体外活性与氟康唑和伊曲康唑针对541株新型隐球菌临床分离株的活性进行了比较。分离株取自脑脊液（396株）、血液（116株）和其他临床标本（29株）。总体而言，ravuconazole（使90%的分离株受到抑制的最低抑菌浓度[MIC(90)]为0.25μg/ml）比伊曲康唑（MIC(90)为0.5μg/ml）或氟康唑（MIC(90)为8μg/ml）活性更强。在被≥16μg/ml氟康唑抑制的分离株中，90.2%被≤1μg/ml的ravuconazole抑制。基于我们的研究结果以及ravuconazole良好的药代动力学特性，我们认为ravuconazole可能对治疗新型隐球菌引起的传染病有用，并且有必要进行进一步的临床研究以证实这些有前景的体外研究结果。